Back to top
more

Aphria Inc. (APHA)

(Delayed Data from NYSE)

$6.94 USD

6.94
5,631,062

-0.19 (-2.66%)

Updated May 3, 2019 04:02 PM ET

After-Market: $7.00 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Baxter (BAX) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Baxter's (BAX) first-quarter earnings benefit from solid segmental performance and growth across all geographies.

Urmimala Biswas headshot

LabCorp's (LH) Q1 Earnings Beat Estimates, Margins Down

by Urmimala Biswas

LabCorp's (LH) Covance Drug Development revenues improve despite COVID-19 hurdles.

Boston Scientific (BSX) Q1 Earnings Miss, Margins Decline

by Zacks Equity Research

The severity of the COVID-19 outbreak takes a toll on Boston Scientific's (BSX) global sales during the first quarter.

Chemed's (CHE) Q1 Earnings Beat Estimates, Margins Improve

by Zacks Equity Research

Chemed's (CHE) first-quarter 2020 results reflect strong segmental performances amid the coronavirus-led economic doldrums.

Henry Schein (HSIC) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Contribution from Henry Schein's (HSIC) medical business in the form of point-of-care antibody rapid test is likely to have boosted Q1 performance amid the coronavirus pandemic.

What's in Store for IDEXX Laboratories (IDXX) in Q1 Earnings?

by Zacks Equity Research

IDEXX's (IDXX) business is likely to have benefited from few cases in which pets were found to be COVID-19 positive globally.

Can IC and PI Arms Drive Boston Scientific (BSX) Q1 Earnings?

by Zacks Equity Research

Boston Scientific's (BSX) business trends in the first two months of the quarter in line with its expectations.

Illumina (ILMN) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Illumina (ILMN) is upbeat about its first-quarter sequencing consumable revenue growth.

ResMed (RMD) Q3 Earnings to Gain From Growing Ventilator Sales

by Zacks Equity Research

ResMed (RMD) is expected to have gained from increased adoption of flagship products and a ramped-up ventilator production capacity in Q3 amid the coronavirus pandemic.

Can Global Industrial Unit Drive Ecolab's (ECL) Q1 Earnings?

by Zacks Equity Research

Ecolab's (ECL) Global Industrial segment is likely to have gained from the Water, Food & Beverage and Life Sciences sub-units in the first quarter.

Cerner (CERN) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Cerner's (CERN) first-quarter results are likely to reflect solid show by Population Health, Revenue Cycle and IT Works.

DexCom (DXCM) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

DexCom's (DXCM) first-quarter performance is likely to reflect rising global awareness of the company's real-time CGM.

Zacks.com featured highlights include: Ionis Pharmaceuticals, Aphria, Tabula Rasa Healthcare, InterDigital and Huron Consulting Group

by Zacks Equity Research

Zacks.com featured highlights include: Ionis Pharmaceuticals, Aphria, Tabula Rasa Healthcare, InterDigital and Huron Consulting Group

Align Technology (ALGN) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Align Technology (ALGN) is expected to have gained from continued adoption of Invisalign system in the first two months of Q1.

Can Diagnostics Aid Hologic (HOLX) Q2 Sales Amid Coronavirus?

by Zacks Equity Research

Strength in segmental businesses is likely to have aided Hologic's (HOLX) performance in second-quarter fiscal 2020 amid the coronavirus-led economic doldrums.

Will LabCorp's (LH) Coronavirus Test Boost Q1 Earnings?

by Zacks Equity Research

LabCorp (LH) is expected to have witnessed a significant fall in its quarterly revenues due to the coronavirus mayhem.

Aphria's Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Aphria.

Sanghamitra Saha headshot

Grab 5 Top Stocks With Strong Earnings Beat Prospects

by Sanghamitra Saha

Invest in top-ranked stocks that are likely to beat their earnings estimates in the upcoming releases.

Can TAVR's SAPIEN 3 Aid Edwards Lifesciences (EW) Q1 Earnings?

by Zacks Equity Research

Robust customer adoption of the HemoSphere all-in-one monitoring platform and TAVR treatments is likely to have driven Edwards Lifesciences' (EW) Q1 revenues.

Company News for Apr 16, 2020

by Zacks Equity Research

Companies in the news are: PGR, APHA, WIT, LYTS

Will Brand Building Efforts Aid Aphria (APHA) in Q3 Earnings?

by Zacks Equity Research

Aphria's (APHA) focus on enhancing its brands and profitability is likely to have boosted its top line in third-quarter fiscal 2020.

Are Options Traders Betting on a Big Move in Aphria (APHA) Stock?

by Zacks Equity Research

Investors need to pay close attention to Aphria (APHA) stock based on the movements in the options market lately.

Aphria Inc. (APHA) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Aphria Inc. (APHA) closed at $2.89, marking a +1.05% move from the previous day.

Aphria Inc. (APHA) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Aphria Inc. (APHA) closed at $2.54, marking a +1.2% move from the previous day.

Aphria Inc. (APHA) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Aphria Inc. (APHA) closed at $2.16, marking a +0.47% move from the previous day.